Revatio (Sildenafil Citrate) Patent Expiration, LOE Window & CMS Spending
Revatio (Sildenafil Citrate) by Viatris: FDA Orange Book LOE 2030-01-31, 26 AB generics, $31.9M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Viatris |
| FDA Application & Pathway | N021845 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-01-31 |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 26 |
| 2024 CMS Total Public Spend | $31.9M |
| 2024 Medicare Part D Spend | $7.2M |
| 2024 Medicaid Spend | $24.7M |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 17.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.